Coles starts FY23 with modest sales growth
Nick Sundich, October 26, 2022
Coles (ASX:COL) reported its Q1 results for FY23 and these turned out positive for the company. The headline revenue growth figure was only 1.3%, but impressive in a time of high inflation and expenditure on hospitality higher than 12 months ago.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Coles records $9.9bn in sales
Coles’ revenue for the 13 weeks from 27 June to 25 September was $9.9bn. $8.8bn of this came from supermarkets, $836m from liquor and $284m from Express.
Liquor was down by 4.3% compared to the prior corresponding period which was inflated by lockdowns. But Express was 8.4% higher as people drove more than they could during lockdowns. Supermarkets was 1.6% higher than the prior corresponding period.
Will the good times continue?
Coles’ results came in spite of the ‘Dropped & Locked’ initiative, which caps prices. In one sense, the results are positive.
But it is important to note, today’s results did not record mention bottom line figures, which would arguably give a clearer picture as to the impacts. Coles may not be as impacted by rising costs being a price setter, but it may be unable to avoid an impact altogether. Investors have sent shares down 1.8% this morning, arguably expecting a better result because supermarkets are the ultimate consumer staple category on the share market.

Coles (ASX:COL) share price chart (Graph: TradingView)
We think it will be interesting to compare its results to that of Woolworths, although its competitor reports on a different calendar so will not be updating shareholders until next month.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Trump vs. Jerome Powell: What Happens to the Market If Powell Is Fired?
The relationship between President Donald Trump and Federal Reserve Chair Jerome Powell has often been tumultuous, particularly around decisions regarding…
Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!
What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…
Anti Woke ETFs: Do they practice what they preach and have they outperformed since Trump’s return to power?
Have you ever heard of so-called ‘Anti Woke ETFs’? If you’re sick of companies that are big on ESG, this…